ARO-APOC3 PFS
Sponsors
Arrowhead Pharmaceuticals Inc.
Conditions
Familial Chylomicronemia Syndrome (FCS)HypertriglyceridemiaHypertriglyceridemia (HTG)Severe hypertriglyceridemia (SHTG)
Phase 3
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
Active, not recruitingCTIS2023-509301-80-00
Start: 2024-11-04Target: 138Updated: 2025-10-24
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)
Active, not recruitingCTIS2023-509300-14-00
Start: 2024-10-31Target: 169Updated: 2026-01-19
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome
Active, not recruitingCTIS2024-514336-24-00
Start: 2022-03-24Target: 21Updated: 2025-10-23
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)
Active, not recruitingCTIS2023-509302-30-00
Start: 2024-11-04Target: 478Updated: 2026-01-19
A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (SHASTA-10 STUDY)
RecruitingCTIS2024-519712-13-00
Start: 2025-12-08Target: 372Updated: 2025-08-27
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
RecruitingCTIS2024-518206-40-00
Start: 2025-11-03Target: 55Updated: 2026-01-12